Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Common Equity: 2011-2025

Historic Common Equity for Enanta Pharmaceuticals (ENTA) over the last 15 years, with Sep 2025 value amounting to $64.7 million.

  • Enanta Pharmaceuticals' Common Equity fell 49.76% to $64.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.7 million, marking a year-over-year decrease of 49.76%. This contributed to the annual value of $64.7 million for FY2025, which is 49.76% down from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Common Equity stood at $64.7 million for FY2025, which was down 49.76% from $128.8 million recorded in FY2024.
  • In the past 5 years, Enanta Pharmaceuticals' Common Equity registered a high of $399.4 million during FY2021, and its lowest value of $64.7 million during FY2025.
  • Moreover, its 3-year median value for Common Equity was $128.8 million (2024), whereas its average is $136.8 million.
  • Data for Enanta Pharmaceuticals' Common Equity shows a maximum YoY tumbled of 49.76% (in 2025) over the last 5 years.
  • Over the past 5 years, Enanta Pharmaceuticals' Common Equity (Yearly) stood at $399.4 million in 2021, then decreased by 19.55% to $321.3 million in 2022, then slumped by 32.55% to $216.7 million in 2023, then tumbled by 40.57% to $128.8 million in 2024, then plummeted by 49.76% to $64.7 million in 2025.